Business
Starpharma hunts for cash as it speeds up COVID nasal spray treatment – Sydney Morning Herald
The Melbourne biotech is in a trading halt as it launches a placement for a COVID treatment it hopes to be ready by next year.
Starpharma shares have been on a tear over the past month since the business started to update the market on progress about the nasal spray. Shares have jumped from $1.41 to $1.60 over the past month.
The nasal spray repurposes Starpharma’s antiviral product SPL7013, which is already used in its sexual health products including condoms. The company hopes the compound will bind to the SARS-COV-2 spike protein and block the virus from attaching to cells.
Earlier this month the company released d…
-
Business21 hours agoThe ultimate Australian stocks to buy and hold for 10+ years
-
Noosa News22 hours agoNew process turns wheat straw and oat husks into sustainable clothing
-
Noosa News18 hours agoSouthern NSW farmers call for financial relief as ongoing drought takes a toll
-
Noosa News17 hours agoLNP Premier David Crisafulli announces ‘Queensland’s royal commission’ into CFMEU